ICER Releases List of Top Drugs with Unsubstantiated Price Hikes in 2021
December 6, 2022
A new report published by the Institute for Clinical and Economic Review (ICER) lays out a list of the top 10 therapeutics that had unsupported price hikes last year. Among the top ten were several high-price drugs that contributed significantly to US drug spending. Seven of the top 10 list were hiked without any new evidence.
According to ICER, “The three drugs assessed that did have important new clinical evidence were Cosentyx® (Secukinumab), Tremfya® (Guselkumab), and Jakafi® (Ruxolitinib). Importantly, however, ICER’s determination that new evidence exists for these three treatments should not be interpreted to mean that the new evidence justifies the level of price increase; a full cost-effectiveness assessment was not conducted.”
To read more, click here.
(Source: ICER, December 6th, 2022)
